MKEAY - MKEAY STOCK NEWS

Mauna Kea Technologies (Euronext: MKEA; OTCQX: MKEAY) and On Target Laboratories have entered a partnership to enhance molecular image-guided procedures for diagnosing lung cancer. This collaboration focuses on interventional pulmonology, utilizing On Target's imaging agents and Mauna Kea's Cellvizio platform to improve diagnostic accuracy of lung biopsies. Lung cancer remains the leading cause of cancer deaths, with a significant need for timely diagnosis. The partnership aims to provide real-time cellular visualization, potentially transforming patient management and outcomes.

Mauna Kea Technologies (OTCQX:MKEAY) has initiated a clinical feasibility study named CLEAR, in partnership with the Lung Cancer Initiative at Johnson & Johnson. This study aims to assess the effectiveness of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy, targeting peripheral lung nodules. The study plans to enroll up to 75 patients across three U.S. centers, evaluating the accuracy of the biopsy needle positioning confirmed by imaging technology. The successful navigation may help reduce the near-miss rate of lung cancer diagnoses.

Mauna Kea Technologies, known for its Cellvizio® platform, announced the publication of its 2022 Financial Calendar. Key dates include the release of 2021 full-year financial results and 2022 first-quarter sales on April 21, 2022, followed by second-quarter and first-half sales on July 21, 2022. The company’s innovative technology provides real-time cellular imaging, aiding medical professionals in disease monitoring and surgical guidance. The press release emphasizes the company's commitment to enhancing the diagnosis and treatment processes across various medical specialties.

Mauna Kea Technologies reported a strong performance in 2021, achieving total sales of €7.70 million, an increase of 18% year-over-year. Notable growth was seen in systems sales, which rose by 24% to €3.19 million, while consumables saw a modest increase of 13%, totaling €3.20 million. However, Q4 consumables sales declined by 5%. The company highlights a 66% growth in Europe, despite challenges from the COVID-19 pandemic affecting global healthcare. Mauna Kea aims to execute a new strategic plan for further growth.

Mauna Kea Technologies (MKEAY) has adopted a board-approved plan to reduce operating expenses by approximately 40%, extending its cash runway to Q4 2023. This strategic shift focuses on leveraging its Cellvizio platform for lung cancer characterization and molecular imaging. The company aims to partner with engineering firms to integrate clinical insights effectively. Key personnel changes include promoting Shu-i Gautheron to CFO and Daryl Donatelli to VP of Global Marketing. The next financial communication is set for January 20, 2022.

Mauna Kea Technologies (OTCQX:MKEAY) has announced a strategic realignment to boost operating efficiency and extend its cash runway. This includes a focus on high-potential applications of its Cellvizio® platform in interventional pulmonology and molecular imaging. Robert Gershon has resigned as CEO, with Nicolas Bouvier appointed as Interim CEO. The board aims to enhance capital efficiency and support ongoing clinical programs, emphasizing the company's unique imaging capabilities to meet clinician and shareholder needs.

Mauna Kea Technologies (OTCQX: MKEAY) recently released a peer-reviewed publication demonstrating the economic advantages of its Cellvizio® technology in managing pancreatic cystic lesions. The study highlights that the use of EUS-nCLE allows for better diagnostic accuracy, downstaging 12% of patients from mucinous to non-mucinous categories, thereby preventing unnecessary surgeries. This results in healthcare savings of approximately $442,438 for 93 patients, equating to $4,757 saved per patient. The findings advocate for broader adoption of Cellvizio in clinical settings.

Mauna Kea Technologies (MKEAY) reported a 23% increase in its total sales for the first nine months of 2021, reaching €5.1 million. However, the third quarter sales decreased by 13% year-over-year to €1.8 million due to COVID-19 disruptions, particularly in the U.S. Despite this, sales of systems rose 36% during the nine-month period. Management anticipates 18%-20% growth in sales for Q4, reflecting improved demand and the execution of their commercial strategy.

Mauna Kea Technologies announces significant advancements following the presentation of 5 communications on its Cellvizio technology at the ERS International Congress 2021. These studies highlight Cellvizio's role in enhancing bronchoscopy techniques, aiding in detecting lung cancer, and improving patient outcomes. Notably, the combination of Cellvizio and robotic-assisted bronchoscopy demonstrated a 93% detection rate of malignancy in patients. The company aims to broaden the adoption of Cellvizio in the pulmonology community.